Antimicrobial resistance is a present and growing global health threat. Currently, at least 700,000 people die each year from drug-resistant infections, which the United Nations warns could rise to 10 million deaths per year by 2050.
To tackle the crisis of AMR, we need to fully understand it. The pharmaceutical industry routinely collects surveillance data to monitor susceptibility of clinical isolates to marketed products, or to fulfil regulatory approval requirements for new products. The open sharing of these data through a single platform will enable researchers to:
Our hope is that the research projects enabled by this platform will further advance understanding, inform decision-making and drive policy changes in the medical community, global organizations such as the United Nations and the World Health Organisation, and wider society.
This AMR Register has been developed by Vivli, with a grant awarded by Wellcome, in support of these aims.
In 2017, Wellcome funded a pilot project run by the Open Data Institute which enabled the launch of an AMR Register which provides information from AMR surveillance programmes generated by the pharmaceutical industry.
Key outcomes of the pilot identified that:
Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community. The platform includes a data repository, in-depth search engine and cloud-based analytics, and harmonizes governance, policy and processes to make sharing data easier. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit amr.vivli.org and follow us on Twitter @VivliCenter.